source
- AstraZeneca’s rare disease drug Wainua fails Phase 3, narrowing path to $80 billion sales goalAstraZeneca announced that its rare disease therapy Wainua did not meet its primary endpoints in a Phase 3 trial, ending plans to broaden the drug’s label for transthyretin amyloidosis cardiomyopat…
- Trump threatens up to 200% tariffs on generic drugs not manufactured in the United StatesPresident Donald Trump announced that his administration will consider imposing steep tariffs on generic medicines that are imported rather than produced in the United States. The proposed tariffs…